MX2024004738A - Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas. - Google Patents
Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas.Info
- Publication number
- MX2024004738A MX2024004738A MX2024004738A MX2024004738A MX2024004738A MX 2024004738 A MX2024004738 A MX 2024004738A MX 2024004738 A MX2024004738 A MX 2024004738A MX 2024004738 A MX2024004738 A MX 2024004738A MX 2024004738 A MX2024004738 A MX 2024004738A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline forms
- preparation
- composition
- quinazoline derivatives
- methoxyquinazolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/14—Adipic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/185—Saturated compounds having only one carboxyl group and containing keto groups
- C07C59/225—Saturated compounds having only one carboxyl group and containing keto groups containing —CHO groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021125016 | 2021-10-20 | ||
| PCT/CN2022/126169 WO2023066296A1 (en) | 2021-10-20 | 2022-10-19 | Crystalline forms of quinazoline derivatives, preparation, composition and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024004738A true MX2024004738A (es) | 2024-05-14 |
Family
ID=86057927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024004738A MX2024004738A (es) | 2021-10-20 | 2022-10-19 | Formas cristalinas de derivados de quinazolina, preparacion, composicion y uso de estas. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20240417403A1 (https=) |
| EP (2) | EP4399207B1 (https=) |
| JP (2) | JP2024539212A (https=) |
| KR (1) | KR20240090181A (https=) |
| CN (4) | CN119317625A (https=) |
| AU (1) | AU2022371540A1 (https=) |
| CA (1) | CA3232101A1 (https=) |
| CL (1) | CL2024001231A1 (https=) |
| CO (1) | CO2024004745A2 (https=) |
| CR (1) | CR20240163A (https=) |
| DK (1) | DK4399207T3 (https=) |
| ES (1) | ES3059167T3 (https=) |
| FI (1) | FI4399207T3 (https=) |
| HR (1) | HRP20260049T1 (https=) |
| IL (1) | IL312004A (https=) |
| LT (1) | LT4399207T (https=) |
| MA (1) | MA66471B1 (https=) |
| MX (1) | MX2024004738A (https=) |
| PE (1) | PE20242106A1 (https=) |
| PL (1) | PL4399207T3 (https=) |
| PT (1) | PT4399207T (https=) |
| RS (1) | RS67641B1 (https=) |
| SI (1) | SI4399207T1 (https=) |
| SM (1) | SMT202600023T1 (https=) |
| WO (1) | WO2023066296A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| WO2025195333A1 (en) | 2024-03-19 | 2025-09-25 | F. Hoffmann-La Roche Ag | Pharmaceutical formulation of erbb2 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| DE69720965T2 (de) | 1996-02-13 | 2004-02-05 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| ATE446294T1 (de) * | 2005-11-15 | 2009-11-15 | Array Biopharma Inc | N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten |
| WO2017148391A1 (zh) * | 2016-03-01 | 2017-09-08 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| EP3516071B1 (en) * | 2016-09-22 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of lung cancer |
| TWI858848B (zh) * | 2018-05-08 | 2024-10-11 | 大陸商迪哲（江蘇）醫藥股份有限公司 | ＥｒｂＢ受體抑制劑 |
| EP4523755A3 (en) * | 2018-09-18 | 2025-06-11 | F. Hoffmann-La Roche AG | Quinazoline derivatives as antitumor agents |
-
2022
- 2022-10-19 IL IL312004A patent/IL312004A/en unknown
- 2022-10-19 PL PL22882901.6T patent/PL4399207T3/pl unknown
- 2022-10-19 DK DK22882901.6T patent/DK4399207T3/da active
- 2022-10-19 CN CN202280070755.1A patent/CN119317625A/zh active Pending
- 2022-10-19 SM SM20260023T patent/SMT202600023T1/it unknown
- 2022-10-19 SI SI202230234T patent/SI4399207T1/sl unknown
- 2022-10-19 ES ES22882901T patent/ES3059167T3/es active Active
- 2022-10-19 LT LTEPPCT/CN2022/126169T patent/LT4399207T/lt unknown
- 2022-10-19 MA MA66471A patent/MA66471B1/fr unknown
- 2022-10-19 EP EP22882901.6A patent/EP4399207B1/en active Active
- 2022-10-19 MX MX2024004738A patent/MX2024004738A/es unknown
- 2022-10-19 HR HRP20260049TT patent/HRP20260049T1/hr unknown
- 2022-10-19 US US18/702,989 patent/US20240417403A1/en active Pending
- 2022-10-19 CN CN202510509201.2A patent/CN120309620A/zh active Pending
- 2022-10-19 PE PE2024000895A patent/PE20242106A1/es unknown
- 2022-10-19 JP JP2024523839A patent/JP2024539212A/ja active Pending
- 2022-10-19 AU AU2022371540A patent/AU2022371540A1/en active Pending
- 2022-10-19 KR KR1020247012414A patent/KR20240090181A/ko active Pending
- 2022-10-19 RS RS20260048A patent/RS67641B1/sr unknown
- 2022-10-19 CN CN202510509243.6A patent/CN120309621A/zh active Pending
- 2022-10-19 CR CR20240163A patent/CR20240163A/es unknown
- 2022-10-19 CN CN202510508208.2A patent/CN120623183A/zh active Pending
- 2022-10-19 PT PT228829016T patent/PT4399207T/pt unknown
- 2022-10-19 CA CA3232101A patent/CA3232101A1/en active Pending
- 2022-10-19 EP EP25217993.2A patent/EP4717689A2/en active Pending
- 2022-10-19 WO PCT/CN2022/126169 patent/WO2023066296A1/en not_active Ceased
- 2022-10-19 FI FIEP22882901.6T patent/FI4399207T3/fi active
-
2024
- 2024-04-16 CO CONC2024/0004745A patent/CO2024004745A2/es unknown
- 2024-04-19 CL CL2024001231A patent/CL2024001231A1/es unknown
-
2025
- 2025-10-17 JP JP2025175882A patent/JP2026027273A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES3059167T3 (en) | 2026-03-19 |
| PT4399207T (pt) | 2026-01-16 |
| SMT202600023T1 (it) | 2026-03-09 |
| JP2026027273A (ja) | 2026-02-18 |
| KR20240090181A (ko) | 2024-06-21 |
| FI4399207T3 (fi) | 2026-01-28 |
| CN120309620A (zh) | 2025-07-15 |
| CA3232101A1 (en) | 2023-04-27 |
| CN120309621A (zh) | 2025-07-15 |
| CN119317625A (zh) | 2025-01-14 |
| CO2024004745A2 (es) | 2024-04-29 |
| SI4399207T1 (sl) | 2026-04-30 |
| RS67641B1 (sr) | 2026-02-27 |
| JP2024539212A (ja) | 2024-10-28 |
| EP4399207A4 (en) | 2025-03-19 |
| LT4399207T (lt) | 2026-02-10 |
| HRP20260049T1 (hr) | 2026-02-27 |
| AU2022371540A1 (en) | 2024-03-21 |
| DK4399207T3 (da) | 2026-02-02 |
| PE20242106A1 (es) | 2024-10-28 |
| IL312004A (en) | 2024-06-01 |
| CN120623183A (zh) | 2025-09-12 |
| CR20240163A (es) | 2024-06-12 |
| MA66471B1 (fr) | 2026-02-27 |
| WO2023066296A1 (en) | 2023-04-27 |
| EP4399207A1 (en) | 2024-07-17 |
| US20240417403A1 (en) | 2024-12-19 |
| EP4399207B1 (en) | 2025-11-26 |
| PL4399207T3 (pl) | 2026-03-23 |
| CL2024001231A1 (es) | 2024-08-09 |
| EP4717689A2 (en) | 2026-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220537A (es) | [1,3]DIAZINO[5,4-d]PIRIMIDINAS COMO INHIBIDORES DE HER2 | |
| JOP20220267A1 (ar) | مركبات أمينو ثيازول تحمل بدائل بصفتها مثبطات لـثنائي أسيل غليسرول كيناز زيتا لتنشيط المناعة | |
| BRPI0513811A (pt) | imidazo [4,5-d] pirimidinas, seus usos e processos de preparação | |
| DOP2000000114A (es) | Oxazolidinonas substituidas y su uso | |
| WO2007007919A3 (en) | Heterocyclic janus kinase 3 inhibitors | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| NO20060113L (no) | Pyrrolo(3,4-c)pyrazolderivater aktive som kinase inhibitorer | |
| NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
| BRPI0113042B8 (pt) | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| ATE355064T1 (de) | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase | |
| CR20240163A (es) | Formas cristalinas de derivados de quinazolina, preparación, composición y uso de estas | |
| JP2005502643A (ja) | 白血病処置のための単独またはｓｔｉ５７１と組み合せたｃ−ｓｒｃインヒビターの使用 | |
| BR0213522B8 (pt) | compostos derivados de hidroxipirimidinona, composição farmacêutica, e, uso de um composto | |
| IL182893A0 (en) | PYRAZOLO-[1,5-a] PYRIMIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| AU2003241345A1 (en) | Use of mastic and its components for the control of microbial infections | |
| WO2021074620A9 (en) | [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors | |
| EP4397375A3 (en) | Isoxazoline parasiticide formulations and methods for treating blepharitis | |
| BR9807950A (pt) | Composto, composição farmacêutica, uso de um composto, e, processos para tratar ou reduzir o risco de doenças ou condições humanas, o risco de doença inflamatória o risco da dor e para a preparação de um composto | |
| MY144897A (en) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| ZA202309969B (en) | Laquinimod formulation for ocular use | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| WO2005120516A3 (en) | Hiv integrase inhibitors |